Jindi Han

424 total citations
29 papers, 327 citations indexed

About

Jindi Han is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Jindi Han has authored 29 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 6 papers in Epidemiology. Recurrent topics in Jindi Han's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Jindi Han is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Jindi Han collaborates with scholars based in China, Ethiopia and United Kingdom. Jindi Han's co-authors include Weiheng Hu, Guangming Tian, Jun Nie, Xiangjuan Ma, Di Wu, Ling Dai, Xiaoling Chen, Sen Han, Jie Zhang and Jian Fang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Cancer.

In The Last Decade

Jindi Han

25 papers receiving 321 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Jindi Han 254 143 57 56 48 29 327
A. Thoelke 108 0.4× 59 0.4× 20 0.4× 75 1.3× 51 1.1× 7 297
Till Plönes 180 0.7× 224 1.6× 44 0.8× 85 1.5× 34 0.7× 53 406
Shiyin Wei 96 0.4× 91 0.6× 15 0.3× 117 2.1× 54 1.1× 21 283
Qionghua Lin 100 0.4× 90 0.6× 51 0.9× 83 1.5× 45 0.9× 12 274
Huiping Qiang 288 1.1× 194 1.4× 30 0.5× 61 1.1× 40 0.8× 20 362
Anna Klimczak 149 0.6× 202 1.4× 15 0.3× 64 1.1× 17 0.4× 32 328
Wanying Guo 202 0.8× 52 0.4× 18 0.3× 72 1.3× 29 0.6× 12 279
Tadasuke Shimokawaji 106 0.4× 143 1.0× 62 1.1× 53 0.9× 43 0.9× 20 300

Countries citing papers authored by Jindi Han

Since Specialization
Citations

This map shows the geographic impact of Jindi Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jindi Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jindi Han more than expected).

Fields of papers citing papers by Jindi Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jindi Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jindi Han. The network helps show where Jindi Han may publish in the future.

Co-authorship network of co-authors of Jindi Han

This figure shows the co-authorship network connecting the top 25 collaborators of Jindi Han. A scholar is included among the top collaborators of Jindi Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jindi Han. Jindi Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cao, Wenli, Sen Han, Lan Mi, et al.. (2025). Immune checkpoint inhibitor-related myocarditis in patients with lung cancer. BMC Cancer. 25(1). 685–685. 3 indexed citations
2.
Tian, Guangming, Jun Nie, Ling Dai, et al.. (2025). Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China. Frontiers in Oncology. 15. 1577607–1577607.
3.
Sun, Shengjie, Jindi Han, Wei Liu, et al.. (2022). Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer. World Journal of Clinical Cases. 10(18). 6069–6081. 2 indexed citations
4.
Tian, Guangming, Xinliang Zhao, Jun Nie, et al.. (2022). The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies. Journal of Thoracic Disease. 14(6). 2201–2212. 1 indexed citations
5.
6.
Wang, Yang, Jun Nie, Ling Dai, et al.. (2021). Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC. Cancer Immunology Immunotherapy. 71(2). 267–276. 4 indexed citations
7.
Chen, Xiaoling, Jun Nie, Ling Dai, et al.. (2021). Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China. Frontiers in Oncology. 11. 607531–607531. 28 indexed citations
8.
Zhang, Jie, Di Wu, Ziran Zhang, et al.. (2021). Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study. Technology in Cancer Research & Treatment. 20. 2203781564–2203781564. 3 indexed citations
9.
Ma, Xu, Jun Nie, Weiheng Hu, et al.. (2020). Diagnosis and Treatment Characteristics of Lung Cancer Patients with Venous Thromboembolism. SHILAP Revista de lepidopterología.
10.
Wu, Di, Jun Nie, Weiheng Hu, et al.. (2020). A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer. International Journal of Cancer. 147(12). 3453–3460. 29 indexed citations
11.
Wu, Di, Jun Nie, Ling Dai, et al.. (2019). Salvage treatment with anlotinib for advanced non‐small cell lung cancer. Thoracic Cancer. 10(7). 1590–1596. 25 indexed citations
12.
Wang, Yang, Jun Nie, Ling Dai, et al.. (2018). Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma. Thoracic Cancer. 10(1). 17–23. 7 indexed citations
13.
Hu, Weiheng, Jian Fang, Jun Nie, et al.. (2017). Efficacy and safety of endostar in the treatment of advanced lung squamous cell carcinoma.. Journal of Clinical Oncology. 35(15_suppl). e20574–e20574.
14.
Hu, Weiheng, Jian Fang, Jun Nie, et al.. (2016). Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer. Medicine. 95(28). e4183–e4183. 11 indexed citations
15.
Wu, Di, Jian Fang, Jun Nie, et al.. (2015). [Effects of Local Radiation Combined with Chemotherapy in the treatment of 
Patients with Extensive-stage Small Cell Lung Cancer].. SHILAP Revista de lepidopterología. 18(5). 272–9. 2 indexed citations
16.
Zhang, Jie, Jing Gao, Yanyan Li, et al.. (2015). Circulating PD‐L1 in NSCLC patients and the correlation between the level of PD‐L1 expression and the clinical characteristics. Thoracic Cancer. 6(4). 534–538. 109 indexed citations
17.
Zhang, Jie, Jian Fang, Jun Nie, et al.. (2015). Dynamic changes of circulating tumor cells during chemotherapy as a prognostic factor in patients with advanced lung cancer.. Journal of Clinical Oncology. 33(15_suppl). e22024–e22024.
18.
Zhang, Jie, Shaolei Li, Jindi Han, et al.. (2014). Retrospective study of surgery versus non‐surgical management in limited‐disease small cell lung cancer. Thoracic Cancer. 5(5). 405–410. 10 indexed citations
19.
Hu, Weiheng, Jian Fang, Jun Nie, et al.. (2014). Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails. Cancer Chemotherapy and Pharmacology. 73(6). 1129–1136. 4 indexed citations
20.
Gao, Wenbin, Jindi Han, & Min Du. (2005). [Observation on efficiency of shelian capsule as adjuvant of embolismic chemotherapy on primary hepatic carcinoma].. PubMed. 25(11). 980–2. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Thoelke Breakdown of academic impact, for papers by Till Plönes Breakdown of academic impact, for papers by Shiyin Wei Breakdown of academic impact, for papers by Qionghua Lin Breakdown of academic impact, for papers by Huiping Qiang Breakdown of academic impact, for papers by Anna Klimczak Breakdown of academic impact, for papers by Wanying Guo Breakdown of academic impact, for papers by Tadasuke Shimokawaji
Rankless by CCL
2026